F09 - When Sweet Turns Sour: Addressing SGLT-2 Inhibitor-Associated Euglycemic DKA

Friday, August 8, 2025

11:30 AM - 12:15 PM MST

CE/CME Hours: .75 CE

Pharmacology Hours: .50 CE

This session explores the pivotal role of SGLT-2 inhibitors in modern diabetes management, focusing on their mechanisms of action, clinical benefits, and potential risks. A special focus will be placed on SGLT-2 inhibitor-associated euglycemic diabetes-related ketoacidosis (DKA), including its defining criteria, underlying mechanisms, risk factors, and clinical data. Attendees will gain practical insights into managing and preventing DKA, including considerations for follow-up care. The session also highlights the critical role of the DCES in adopting a person-centered approach to maximize the benefits of SGLT-2 inhibitors while minimizing risks. Participants will leave equipped with actionable tools to address therapeutic inertia while promoting safe medication use.

Disclosure(s):

Jennifer Rosselli, PharmD, BCACP, BC-ADM, CDCES: Medtronic, Inc.: Consultant / Advisory Board (Ongoing)

Raja Hanania, BSc, RPh, BCPS, CDM, CDCES, LDE, FISHP: Novo Nordisk: Speakers' Bureau (Ongoing)

Primary Presenter(s)

Jennifer Rosselli, PharmD, BCACP, BC-ADM, CDCES (she/her/hers)

Clinical Professor
Southern Illinois University Edwardsville School of Pharmacy
Collinsville, Illinois

Disclosure(s): Medtronic, Inc.: Consultant / Advisory Board (Ongoing)

Co-Presenter(s)

Raja A. Hanania, BSc, RPh, BCPS, CDM, CDCES, LDE, FISHP

Clinical Pharmacy Specialist/ Adjunct Lecturer in Pharmacology and Toxicology
Indiana University Health Bloomington Hospital and Indiana University School of Medicine
Bloomington, Indiana

Disclosure(s): Novo Nordisk: Speakers' Bureau (Ongoing)

Session Host(s)

Starlin Haydon-Greatting, MS, MPH, BSPharm, RPh, CDM, FADCES, FAPhA

Director of Clinical Programs and Population Health
SHG Clinical Consulting/Illinois Pharmacists Association
Springfield, Illinois

Disclosure information not submitted.